HealthIs Alzheimer’s drug donanemab really a 'turning point' for treatment? The experimental drug donanemab slows the progression of Alzheimer's disease compared with a placebo, but the effect may not be large enough to be noticed by people with the condition or their families News
LifeProbiotics shield corals from deadly tissue loss disease A bacterial treatment for coral stopped or slowed 68 per cent of infections with stony coral tissue loss disease in the lab, and it prevented the spread of the disease as well News